While ProQR Therapeutics N.V has underperformed by -3.01%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRQR fell by -43.67%, with highs and lows ranging from $4.62 to $1.29, whereas the simple moving average fell by -45.21% in the last 200 days.
On March 10, 2025, Citigroup Upgraded ProQR Therapeutics N.V (NASDAQ: PRQR) to Buy. A report published by Oppenheimer on January 10, 2025, Initiated its previous ‘Outperform’ rating for PRQR. Raymond James also Upgraded PRQR shares as ‘Strong Buy’, setting a target price of $14 on the company’s shares in a report dated October 29, 2024. JMP Securities March 30, 2023d its ‘Mkt Perform’ rating to ‘Mkt Outperform’ for PRQR, as published in its report on March 30, 2023. Cantor Fitzgerald’s report from December 22, 2022 suggests a price prediction of $5 for PRQR shares, giving the stock a ‘Overweight’ rating. Citigroup also rated the stock as ‘Neutral’.
Analysis of ProQR Therapeutics N.V (PRQR)
Further, the quarter-over-quarter increase in sales is 30.09%, showing a positive trend in the upcoming months.
One of the most important indicators of ProQR Therapeutics N.V’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -43.72% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.95, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and PRQR is recording 461.18K average volume. On a monthly basis, the volatility of the stock is set at 6.15%, whereas on a weekly basis, it is put at 7.39%, with a loss of -19.88% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.67, showing growth from the present price of $1.29, which can serve as yet another indication of whether PRQR is worth investing in or should be passed over.
How Do You Analyze ProQR Therapeutics N.V Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 32.74%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 42.39% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
